Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis.

EBioMedicine - 1 Sept 2024

Fu Kai, Si Shucheng, Jin Xinzhong, Zhang Yan, Duong Vicky, Cai Qianying, Li Guangyi, Oo Win Min, Zheng Xianyou, Boer Cindy G, Zhang Yuqing, Wei Xiaojuan, Zhang Changqing, Gao Youshui, Hunter David J

Abstract excerpt

BACKGROUND: Osteoarthritis is a leading cause of disability, and disease-modifying osteoarthritis drugs (DMOADs) could represent a pivotal advancement in treatment. Identifying the potential of antidiabetic medications as DMOADs could impact patient care significantly. METHODS: We designed a comprehensive analysis pipeline involving two-sample Mendelian Randomization (MR) (genetic proxies for antidiabetic drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genome-Wide Association Study
Share to Hypoglycemic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mendelian Randomization Analysis

Share to Molecular Targeted Therapy

Share to Osteoarthritis

Share to Polymorphism, Single Nucleotide

Share to Quantitative Trait Loci

Source

Open in PubMed Open full text

Identifiers

PMID: 39153411
DOI: 10.1016/j.ebiom.2024.105285
PMCID: PMC11378937

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring antidiabetic drug targets as potential disease-modifying agents in osteoarthritis.PMID 39153411Read ↗

Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.Semantic proximity Read ↗

Evaluating the impact of metformin targets on the risk of osteoarthritis: a mendelian randomization study.Semantic proximity Read ↗

The Impact of Blood Glucose and Antidiabetic Medications on Osteoarthritis: A Mendelian Randomization StudySemantic proximity Read ↗

Individualized Management of Osteoarthritis: The Role of Pharmacogenomics to Optimize Pain TherapySemantic proximity Read ↗

Exploring the regulatory mechanisms of antidiabetic drugs on osteoporosis and Bone mineral density.Semantic proximity Read ↗

Repurposing antidiabetic drugs for rheumatoid arthritis: results from a two-sample Mendelian randomization study.Semantic proximity Read ↗

Pathways targeted by antidiabetes drugs are enriched for multiple genes associated with type 2 diabetes risk.Semantic proximity Read ↗

Unraveling the shared genetic architecture of osteoarthritis and metabolic traits through multi-omics insights.Semantic proximity Read ↗

The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.Semantic proximity Read ↗

Identification and validation of transcriptome-wide association study-derived genes as potential druggable targets for osteoarthritisSemantic proximity Read ↗

Identification of therapeutic targets in osteoarthritis by combining heterogeneous transcriptional datasets, drug-induced expression profiles, and known drug-target interactionsSemantic proximity Read ↗

A novel disease-modifying osteoarthritis drug candidate targeting Runx1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.